FUNDAMENTALS · Fundamentals · CA Healthcare

AbCellera Biologics (ABCL) Fundamentals 2026 — Revenue Analysis | SniperIQ

AbCellera Biologics (ABCL) is a CA-listed Healthcare company in Biotechnology with a market capitalization of

.8B, trading at $5.86 on the NASDAQ. This SniperIQ fundamentals page covers AbCellera Biologics's valuation, profitability (net margin -181.7%), revenue ($75M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
.8B
Net Margin-181.7%
Revenue (FY25)$75M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is AbCellera Biologics's market cap?

AbCellera Biologics (ABCL) has a market capitalization of approximately

.8B, trading at $5.86 on the NASDAQ. Market cap moves with the live share price.

What is AbCellera Biologics's P/E ratio?

AbCellera Biologics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is AbCellera Biologics?

AbCellera Biologics runs a net profit margin of -181.7%, a gross margin of 79.1%, and an operating margin of -267.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does AbCellera Biologics generate?

AbCellera Biologics reported revenue of $75M for fiscal year 2025, with net income of -

46M and earnings per share (EPS) of -0.49. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does AbCellera Biologics pay a dividend?

AbCellera Biologics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is AbCellera Biologics financially healthy?

AbCellera Biologics carries a debt-to-equity ratio of 0.15x and a current ratio of 14.05x, with a market beta of 1.15. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is AbCellera Biologics a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For AbCellera Biologics (ABCL) the key facts are: market cap

.8B, revenue $75M, 52-week range 2.745-8.44. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track AbCellera Biologics's full fundamentals live

Get AbCellera Biologics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Generate Biomedicines (GENB) fundamentals · Mineralys Therapeutics (MLYS) fundamentals · Chi Sheng Pharma & Biotech (4111) fundamentals · ANI Pharmaceuticals (ANIP) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons